US Stock Insider Trading | Viking Therapeutics Disclosed One Insider Transaction on March 10

K-LinePoet · 2026-03-24T02:58:51+00:00

On March 10, 2026, Viking Therapeutics executive Aubuchon Neil William purchased 4,475 shares in a transaction totaling approximately $149,000. The company is dedicated to developing novel metabolic and endocrine disorder therapies, with multiple candidate drugs currently in clinical trials.

K-LinePoet

2026-03-24 02:58:51

Abstract generation in progress

On March 10, 2026, Viking Therapeutics (VKTX) disclosed an insider trade. Executive Aubuchon Neil William purchased 4,475 shares.

【Recent Insider Trades】

Disclosure Date	Position	Name	Trade Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 10, 2026	Executive	Aubuchon Neil William	March 10, 2026	Buy	4,475	33.50	$149,900
January 5, 2026	Executive	ZANTE GREG	January 5, 2026	Sell	10,300	34.24	$352,600
January 5, 2026	Director	Lian Brian	January 5, 2026	Sell	132,500	32.29	$4,277,000
January 5, 2026	Director	Lian Brian	January 5, 2026	Sell	6,400	35.07	$224,400
January 5, 2026	Executive	ZANTE GREG	January 5, 2026	Sell	32,000	32.30	$1,032,000
January 5, 2026	Executive	ZANTE GREG	January 5, 2026	Sell	13,900	33.38	$464,200
January 5, 2026	Director	Lian Brian	January 5, 2026	Sell	41,300	34.22	$1,412,400
January 5, 2026	Director	Lian Brian	January 5, 2026	Sell	53,300	33.38	$1,778,300
January 5, 2026	Executive	ZANTE GREG	January 5, 2026	Sell	1,500	32.09	$48,100
January 5, 2026	Executive	Mancini Marianna	January 5, 2026	Sell	13,600	33.37	$453,900

【Company Information】

Viking Therapeutics, Inc. was incorporated in Delaware on September 24, 2012. The company is a clinical-stage biopharmaceutical company focused on developing novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company holds exclusive worldwide rights to a licensed ligand small molecule portfolio with five candidate drugs in clinical or preclinical development. The lead clinical program is VK0612, an oral medication for type 2 diabetes, one of the largest global health challenges, currently in Phase 2b trials, ranking first among similar drugs. The second clinical program, VK5211, aims to treat a complex disease characterized by uncontrolled muscle wasting in cancer cachexia. VK5211 is a non-steroidal selective androgen receptor modulator, or SARM.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes